跳至主要内容
临床试验/KCT0003322
KCT0003322已完成未知

A human study for evaluating effectiveness and safety of Theracurmin CR-033P on antioxidant capacity

Chungnam National University0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 65(Year)(—)
性别
All

入选标准

  • 1) Subject who voluntarily agree to participate and signs informed consent form
  • 2) Men and women aged 20 to under 65.
  • 3) fulfill the current workout habits or diet habits during the study.

排除标准

  • 1) Impossible to performa treadmill activity
  • 2) Continuous intensive workout (more than 1.5 hours a week) within 3 months from the first visit
  • 3) Chronic smoker (= 10 cigarettes / day)
  • 4) Intake more than 420 g of pure alcohol a week (Soju 7bottles/week, 1bottle/day) or an alcoholic
  • 5) Recommended Food Score > 36
  • 6) BMI<18.5 or BMI=30
  • 7) Controlling body weight or have changed of body weight more than 4kg within 4 weeks before the first visit
  • 8) Comply the following categories
  • - Have following diseases or taking relevant medicines: Systemic infection, severe cardiovascular disease (hypertension, stroke), digestive system disease, kidney disease, thyroid disease, autoimmune disease, malignant tumor, multisystem failure, inflammatory bowel disease, uncontrolled meantal illness, HIV
  • - Those who have received organ transplants and bone marrow transplants
  • - Those who taking steroids, antibiotics, and anti-inflammatory drugs (NSAIDs) continuously within 1 month before the first visit
  • - Therapeutic uses of coumadin, aspirin, or other medications that influence hemostasis within three weeks of the first visit.
  • 9) Continuous consumption of health functional food(Coenzyme Q10,antioxidantsmultivitamin etc), and medicinal herbs within 1 months before the first visit
  • 10) Donated blood within 1 month before the first visit
  • 11) Known hypersensitivity to study product or any ingredient in study product
  • 12) Pregnant or lactating women
  • 13) Participation in other human study within 1 month before the first visit
  • 14) Any condition that the principal investigator believes may put the subjects at under risk

研究者

相似试验

A human study for evaluating effectiveness and... | 临床试验